Who are Metformin / Pioglitazone Pill's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Metformin, Pioglitazone, metformin and rosiglitazone, Metformin and Pioglitazone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metformin-pioglitazone-pill.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Metformin / Pioglitazone Pill — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metformin / Pioglitazone Pill (Metformin / Pioglitazone Pill) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antidiabetic combination (biguanide + thiazolidinedione). Area: Diabetes.

marketed Antidiabetic combination (biguanide + thiazolidinedione) AMPK activation (metformin); PPAR-γ (pioglitazone) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Metformin / Pioglitazone Pill (Metformin / Pioglitazone Pill) — University of Catanzaro. This combination reduces blood glucose by decreasing hepatic glucose production (metformin) and improving insulin sensitivity in peripheral tissues (pioglitazone).

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Metformin / Pioglitazone Pill TARGET	Metformin / Pioglitazone Pill	University of Catanzaro	marketed	Antidiabetic combination (biguanide + thiazolidinedione)	AMPK activation (metformin); PPAR-γ (pioglitazone)
Metformin, Pioglitazone	Metformin, Pioglitazone	Khyber Medical University Peshawar	marketed	Antidiabetic combination (biguanide + thiazolidinedione)	AMPK (metformin); PPARγ (pioglitazone)
metformin and rosiglitazone	metformin and rosiglitazone	New York Medical College	marketed	Antidiabetic combination (biguanide + thiazolidinedione)	AMPK (metformin); PPAR-γ (rosiglitazone)
Metformin and Pioglitazone	Metformin and Pioglitazone	King Edward Medical University	marketed	Antidiabetic combination (biguanide + thiazolidinedione)	Metformin: AMP-activated protein kinase (AMPK) pathway; Pioglitazone: PPAR-gamma

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antidiabetic combination (biguanide + thiazolidinedione) class)

Khyber Medical University Peshawar · 1 drug in this class
King Edward Medical University · 1 drug in this class
New York Medical College · 1 drug in this class
University of Catanzaro · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Metformin / Pioglitazone Pill — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-pioglitazone-pill. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab